American Journal

ACADEMY OF NUTRITION AND DIETETICS COMMENDS LEGISLATION TO INCREASE ACCESS TO CARE FOR PEOPLE WITH PREDIABETES

Retrieved on: 
onsdag, november 8, 2023
Social Security Amendments of 1965, MNT, Education, Health, Food, Medicare, Academy of Nutrition and Dietetics, Kidney failure, Congress, The American Journal of Clinical Nutrition, Blood pressure, Diabetes, Dietitian, Research, Prediabetes, Conditional sentence, CDC, Risk, Type 2 diabetes, Type 2, Nutrition, Nutritionist, RDN, American Journal, Waist, Death, Pharmaceutical industry, Nursing, Dietary supplement

Chicago, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics commends U.S. Sens.

Key Points: 
  • Chicago, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics commends U.S. Sens.
  • Medicare covers screening for participants with Type 2 diabetes and medical nutrition therapy for those with diabetes, but not those with prediabetes.
  • A recent study by the Academy of Nutrition and Dietetics published in T he American Journal of Clinical Nutrition confirmed the value of registered dietitian nutritionists and the effectiveness of medical nutrition therapy in addressing prediabetes.
  • “The Academy calls on Congress to pass this important bill to ensure Medicare participants with prediabetes have access to the care they deserve.”
    Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world’s largest organization of food and nutrition professionals.

David J. Meyers, Ph.D., honored with the 2023 AJMC® Seema S. Sonnad Emerging Leader in Managed Care Research Award

Retrieved on: 
tisdag, november 7, 2023
Brown University School of Public Health, Health policy, Seema, Mentorship, Health, Public health, Interest group, AJMC, Research, Student, The American Journal of Managed Care, American Journal, Doctor of Philosophy, Nursing, Management, Medicare, Policy

CRANBURY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC), the leading peer-reviewed journal dedicated to issues in managed care, is thrilled to announce that David J. Meyers, Ph.D., has been recognized with the prestigious 2023 AJMC Seema S. Sonnad Emerging Leader in Managed Care Research Award.

Key Points: 
  • CRANBURY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC), the leading peer-reviewed journal dedicated to issues in managed care, is thrilled to announce that David J. Meyers, Ph.D., has been recognized with the prestigious 2023 AJMC Seema S. Sonnad Emerging Leader in Managed Care Research Award.
  • Meyers’ commitment to advancing managed care research is truly commendable,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences®, parent company of AJMC.
  • “He exemplifies the qualities that the Seema S. Sonnad Emerging Leader in Managed Care Research Award seeks to celebrate, and we are proud to honor him for his achievements.”
    The award was established in honor of Seema S. Sonnad, Ph.D., former associate editor of AJMC, who passed away in June 2015.
  • Dr. Sonnad served as a mentor to many young researchers and was the inspiration for an award that recognizes individuals who exemplify the spirit of innovation and leadership in managed care research.

Park Royal Hospital Offers Inpatient & Outpatient Electroconvulsive Therapy

Retrieved on: 
tisdag, november 7, 2023
The American Journal of Psychiatry, Patient, Suicide, Education, The Lancet, Psychiatry, Electricity, Fear, Electroconvulsive therapy, Risk, Suicidal ideation, ECT, Brain, Depression, Safety, American Journal, Anesthesia, Death, Mental health, Pharmaceutical industry

FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.

Key Points: 
  • FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.
  • At Park Royal Hospital, ECT is available on an inpatient and outpatient basis and is delivered by a trained team of professionals.
  • Electroconvulsive therapy involves using a mild electrical current to stimulate the brain to produce a brief seizure while the patient is under general anesthesia.
  • Those who are interested in receiving ECT at Park Royal Hospital do not need a referral to inquire about treatment and can begin the admissions process anytime.

TrustPoint Hospital Offers Electroconvulsive Therapy in Inpatient & Outpatient Programs

Retrieved on: 
tisdag, november 7, 2023
The American Journal of Psychiatry, Suicide, The Lancet, Psychiatry, Electroconvulsive therapy, Quality of life, Risk, Suicidal ideation, ECT, Depression, Safety, American Journal, Patient, Mental health, Pharmaceutical industry, Nursing

MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.

Key Points: 
  • MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are struggling with severe symptoms of certain mental health disorders.
  • TrustPoint Hospital offers inpatient and outpatient programs for patients who have a range of behavioral health concerns and need focused support.
  • ECT is available in all TrustPoint programs for adults age 18 and older.
  • “At TrustPoint Hospital, we’re committed to providing safe, efficient care that can positively transform patients’ quality of life,” said Brianna Motley, director of business development at TrustPoint.

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
måndag, november 6, 2023
Post-traumatic stress disorder, FDA, Yale School of Medicine, Opioid use disorder, Standard of care, Intelligence, Government, Public Health Service Act, White House, Dexmedetomidine, Opioid epidemic, BID, Federal Food, Drug, and Cosmetic Act, Federation, Addiction, Xylazine, Psychiatry, COWS, Recreational drug use in Kenya, Locus coeruleus, Pharmacokinetics, OUD, National Institute on Drug Abuse, NIDA, Columbia University, NIH, Safety, Public, American Journal, Minneapolis Veterans Affairs Health Care System, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Fentanyl, Bangladesh Technical Education Board, RTI International, United States Public Health Service, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Key Points: 
  • NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.
  • After this time, BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
  • “With BXCL501, we are excited about the potential to treat patients who are physically dependent on illicit and prescription opioids.
  • In addition to OUD as an indication, BioXcel Therapeutics has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder and alcohol use disorder.

The Institute for Value-Based Medicine® from The American Journal of Managed Care® Hosts Event to Address Food Insecurity, Obesity and Chronic Conditions in Louisiana

Retrieved on: 
torsdag, november 2, 2023
Across, MMM, Public health, Louisiana State University Agricultural Center, Food security, Health, Obesity, MPH, LDN, State, Diabetes, Food, Organization, Population health, Pennington Biomedical Research Center, Governing boards of colleges and universities in the United States, Dementia, Ochsner Health System, Death, Quality of life, Conditional sentence, School, The American Journal of Managed Care, Health equity, Food science, Partnership, Poverty, Strategic planning, Lead, Nutrition, RDN, FACP, Cancer, American Journal, Student Success Act, Pennington, Louisiana State University, LSU, Cardiovascular disease, IVBM, Pharmaceutical industry, Management, Nursing, MD, Wellness

The Institute for Value-Based Medicine (IVBM) is renowned for promoting value-based care and advancing healthcare practices.

Key Points: 
  • The Institute for Value-Based Medicine (IVBM) is renowned for promoting value-based care and advancing healthcare practices.
  • This upcoming event brings together panels of distinguished healthcare and community experts who will delve into the latest innovations of value-based care.
  • Together, they will discuss ways to address food insecurity, obesity and chronic conditions, which are major challenges in Louisiana.
  • Lacking access to nutritional food can lead to or worsen chronic conditions, or those that require ongoing medical attention.

Castle Biosciences Reports Third Quarter 2023 Results

Retrieved on: 
torsdag, november 2, 2023
General Health, Medical Devices, Other Health, Health, Medical Supplies, Adjustment, Laboratory, EAC, Metastasis, Innovation, The American Journal of Gastroenterology, Physician, Esophageal cancer, New York State Department of Health, EBITDA, Net, News, Cancer, GAAP, BE, Acquisition, Memorial Sloan Kettering Cancer Center, Sentinel lymph node, Workplace, Purpose, Risk, Compensation, Webcast, LGD, Question and Answer, Depreciation, HGD, Depression, American Journal, Table, Investment, Patient, Compensation and benefits, Pharmaceutical industry, Lithium, Video game, Film industry, Cryptocurrency, Clothing, Birth control, Medical imaging, Real estate

Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:

Key Points: 
  • Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:
    DecisionDx®-Melanoma test reports delivered in the quarter were 8,559, compared to 7,354 in the third quarter of 2022, an increase of 16%.
  • DecisionDx®-SCC test reports delivered in the quarter were 2,820, compared to 1,636 in the third quarter of 2022, an increase of 72%.
  • MyPath® Melanoma test reports delivered in the quarter were 1,011, compared to 834 MyPath Melanoma and DiffDx®-Melanoma aggregate test reports in the third quarter of 2022, an increase of 21%.
  • Castle Biosciences will hold a conference call on Thursday, Nov. 2, 2023, at 4:30 p.m. Eastern time to discuss its third quarter 2023 results and provide a corporate update.

American Journal of Endocannabinoid Medicine (AJEM) Emerges as Premier Resource for Healthcare Professionals to Explore the Endocannabinoid System

Retrieved on: 
måndag, oktober 30, 2023
Research, Cannabis, Other Health, Alternative Medicine, Health, Pharmaceutical, General Health, Science, Natural Resources, Online, Knowledge, Health care, ECS, Physician, Medicine, News, Material, Editorial board, Education, American Journal, Medical device, Nursing

The medical community's understanding of the endocannabinoid system (ECS) has been greatly enhanced with the launch of the American Journal of Endocannabinoid Medicine (AJEM) .

Key Points: 
  • The medical community's understanding of the endocannabinoid system (ECS) has been greatly enhanced with the launch of the American Journal of Endocannabinoid Medicine (AJEM) .
  • AJEM has emerged as the leading resource for healthcare professionals seeking comprehensive and high-level insights into the intricate world of the ECS.
  • Healthcare providers, particularly physicians and medical professionals, are increasingly recognizing the significance of the endocannabinoid system in human health.
  • The American Journal of Endocannabinoid Medicine (AJEM) is the leading online platform dedicated to educating healthcare professionals on medicines that engage with the endocannabinoid system (ECS).

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Retrieved on: 
måndag, oktober 23, 2023
Research, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, General Health, Science, Education, Patient, American College, UC, The American Journal of Gastroenterology, LANCL2, ACG, Lipid metabolism, Safety, American College of Gastroenterology, Ulcerative colitis, Abstract, New Drug Application, Biomarker, NDA, Neutrophil, American Journal, Gene expression, CD, Pharmaceutical industry, Medical device, Medical imaging

Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).

Key Points: 
  • Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).
  • Title: Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Crohn’s Disease.
  • Title: Transcriptional Analysis of Colonic Biopsies from Patients with Ulcerative Colitis Treated with Omilancor.
  • Additionally, the peer-reviewed accepted abstracts will be published verbatim in a special supplement to the October 2023 issue of The American Journal of Gastroenterology.

FREE INJURY PREVENTION AND FALL-RISK SCREENINGS OFFERED FOR ASHEVILLE ADULTS AT BENCHMARK PHYSICAL THERAPY THROUGH NOVEMBER 30

Retrieved on: 
torsdag, oktober 19, 2023
Benchmark, Falls, Research, American Journal of Epidemiology, Falling, Cerebral palsy, Seattle Construction and Drydock Company, Parkinson's disease, DPT, Multimedia, Clinic, CDC, OCS, Risk, MS, PT, Centers for Disease Control and Prevention, DSM-IV codes, Osteoporosis, American Journal, Patient, Death, Seattle, Hersch, Nursing

To help you be proactive in taking preventive measures, Benchmark Physical Therapy is offering complimentary fall risk screenings through November 30.

Key Points: 
  • To help you be proactive in taking preventive measures, Benchmark Physical Therapy is offering complimentary fall risk screenings through November 30.
  • The free screenings involve answering a series of health questions followed by balance, stability, strength, and agility tests.
  • "By determining whether an individual is at risk, we can recommend intervention strategies, such as physical therapy," says Blake Hersch, PT, DPT, OCS, Partner, and Clinic Director for Benchmark Physical Therapy in Asheville.
  • Benchmark Physical Therapy is a member of the Upstream Rehabilitation family, the nation's largest dedicated provider of out-patient physical therapy services with more than 1,200 U.S. locations.